









Markets
/
Stocks
/
nasdaq-amgn
/

Amgen Inc

AMGN

341.280USD

-3.400-0.99%

Market hours （ET）Quotes delayed by 15 min

183.78BMarket Cap

26.21P/E TTM



Amgen Inc

341.280

-3.400-0.99%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Amgen Inc

Currency: USD Updated: 2026-02-02

Key Insights

Amgen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 334.93.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amgen Inc's Score

Industry at a Glance

Industry Ranking

26 / 159

Overall Ranking

76 / 4529

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Amgen Inc Highlights

StrengthsRisks

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.

Fairly Valued

The company’s latest PE is 26.47, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 451.47M shares, increasing 0.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 13.71K shares of this stock.

Analyst Rating

Based on 35 analysts

Hold

Current Rating

334.933

Target Price

-2.03%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-02

The current financial score of Amgen Inc is 8.78, ranking 37 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 9.56B, representing a year-over-year increase of 12.40%, while its net profit experienced a year-over-year increase of 13.64%.

Score

Industry at a Glance

Previous score

8.78

Change



Financials

6.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Amgen Inc's Company Valuation

Currency: USD Updated: 2026-02-02

The current valuation score of Amgen Inc is 7.15, ranking 95 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 26.47, which is 118.59% below the recent high of 57.86 and 45.32% above the recent low of 14.47.

Score

Industry at a Glance

Previous score

7.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-02

The current earnings forecast score of Amgen Inc is 6.97, ranking 123 out of 159 in the Pharmaceuticals industry. The average price target is 323.50, with a high of 400.00 and a low of 180.00.

Score

Industry at a Glance

Previous score

6.97

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 35 analysts

Hold

Current Rating

334.933

Target Price

-2.03%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-02

The current price momentum score of Amgen Inc is 9.22, ranking 29 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 359.22 and the support level at 324.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.231

Buy

RSI(14)

58.481

Neutral

STOCH(KDJ)(9,3,3)

66.304

Neutral

ATR(14)

8.157

High Vlolatility

CCI(14)

40.703

Neutral

Williams %R

25.609

Buy

TRIX(12,20)

0.218

Sell

StochRSI(14)

21.772

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

344.608

Sell

MA10

343.915

Sell

MA20

336.357

Buy

MA50

333.168

Buy

MA100

315.297

Buy

MA200

301.234

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-02

The current institutional shareholding score of Amgen Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.20%, representing a quarter-over-quarter decrease of 0.10%. The largest institutional shareholder is The Vanguard, holding a total of 54.58M shares, representing 10.14% of shares outstanding, with 3.54% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

53.62M

-0.44%

State Street Investment Management (US)

29.30M

-0.18%

BlackRock Institutional Trust Company, N.A.

28.53M

-1.06%

Capital International Investors

19.19M

+1.49%

Capital World Investors

18.80M

+11.48%

Charles Schwab Investment Management, Inc.

13.55M

+5.10%

Geode Capital Management, L.L.C.

13.27M

+1.91%

Invesco Capital Management (QQQ Trust)

12.08M

+7.05%

PRIMECAP Management Company

Star Investors

9.71M

-8.69%

Morgan Stanley Smith Barney LLC

8.89M

+0.87%

Risk Assessment

Currency: USD Updated: 2026-02-02

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Amgen Inc is 8.95, ranking 19 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Amgen Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.